Table 2 Effectiveness of adalimumab at week 12 in patients with ankylosing spondylitis by subgroup of enthesitis or peripheral arthritis or both
No enthesitis + no arthritis (n = 457) | Enthesitis + no arthritis (n = 512) | Arthritis + no enthesitis (n = 107) | Enthesitis + arthritis (n = 174) | Pvaluea | |
|---|---|---|---|---|---|
Median First quartile, third quartile [95% confidence interval] | |||||
BASDAI, 0 to 10 | |||||
Baseline | 5.9 4.9, 6.9 | 6.4 5.4, 7.5 | 6.7 5.7, 7.7 | 6.6 5.7, 7.6 | < 0.001 |
Week 12 | 2.1 0.8, 4.1 | 2.6 1.1, 5.1 | 3.1 1.5, 4.8 | 2.7 1.2, 5.0 | |
Change from baseline to week12 | -3.6 -4.8, -1.7 [-3.8 to -3.3] | -3.4 -4.9, -1.5 [-3.7 to -3.1] | -3.1 -5.0, -1.8 [-4.0 to -2.7] | -3.5 -4.9, -1.7 [-3.7 to -2.9] | 0.813 |
BASFI, 0 to 10 | |||||
Baseline | 4.9 3.4, 6.7 | 5.7 4.0, 7.3 | 5.8 3.7, 7.0 | 6.0 4.3, 7.5 | < 0.001 |
Week 12 | 2.2 1.0, 4.3 | 2.7 1.0, 5.1 | 3.1 1.4, 5.3 | 2.8 1.3, 5.3 | |
Change from baseline to week12 | -1.9 -3.6, -0.7 [-2.1 to -1.7] | -2.1 -3.8, -0.6 [-2.4 to -1.7] | -1.8 -3.2, -0.7 [-2.2 to -1.5] | -1.9 -3.7, -0.5 [-2.2 to -1.5] | 0.828 |
Patient's Global Assessment of disease activity, 0- to 100-mm visual analog scale | |||||
Baseline | 67 49, 80 | 71 53, 83 | 72 54, 81 | 72 53, 83 | 0.004 |
Week 12 | 21 8, 46 | 24 8, 52 | 25 11, 48 | 26 10, 52 | |
Change from baseline to week12 | -35 -58, -14 [-40 to -32] | -38 -59, -15 [-42 to -34] | -39 -61, -13 [-48 to -26] | -33 -57, -12 [-41 to -24] | 0.806 |
C-reactive proteinb, mg/dL | |||||
Baseline | 1.2 0.6, 2.5 | 1.2 0.5, 2.4 | 1.5 0.8,3.6 | 1.3 0.6, 3.4 | 0.448 |
Week 12 | 0.4 0.2, 0.8 | 0.4 0.2, 0.8 | 0.6 0.2, 1.5 | 0.4 0.1, 0.9 | |
Change from baseline to week12 | -0.7 -2.1, -0.1 [-0.9 to -0.6] | -0.8 -1.7, -0.2 [-1.0 to -0.7] | -1.4 -1.7, -0.1 [-1.0 to -0.4] | -0.7 -2.6, -0.1 [-1.3 to -0.4] | 0.857 |